News Breaks |
|
|
| July 30, 2012 |
| 16:03 EDT |  | VRTX | Vertex announces positive results for Nucleotide Analogue in hepatitis C
Vertex Pharmaceuticals Incorporated and its collaborator Alios BioPharma announced positive results from a viral kinetic study of the nucleotide analogue ALS-2200 for the treatment of hepatitis C. There was a median 4.54 log10 reduction in hepatitis C virus (HCV) RNA in people with genotype 1 chronic hepatitis C who were new to treatment (n=8) after seven days of dosing with 200 mg of ALS-2200 once daily. ALS-2200 was well-tolerated in this study, and no patients discontinued due to adverse events. Based on these data, Vertex plans to begin Phase 2 studies this year of 12-week all-oral regimens including ALS-2200 in people with genotype 1 hepatitis C, pending discussions with regulatory agencies. |
|
|
News For VRTX From The Last 14 Days Check below for free stories on VRTX the last two weeks. |
|
|
| June 18, 2013 |
| 11:43 EDT |  | VRTX | Options with decreasing implied volatility: PVH VRTX EWG
 Subscribe for More Information |
|
| 08:36 EDT |  | VRTX | Elan shares could be worh $19 in a buyout, says Jefferies
Jefferies raised its price target for shares of Elan (ELN) to $19 from $14, reflecting what it sees as the value of the company in a takeout scenario. The firm says Elan management suggested they would be open to sale in the $15-$20 per share range. Jefferies believes a high taxpaying suitor could pay the upper end of that range, and lists Allergan (AGN), Regeneron (REGN), Vertex (VRTX), Alexion (ALXN), Zoetis (ZTS), Mylan (MYL) and Perrigo (PRGO) as potential acquirers for Elan. Shares of Elan are up 13c to $13.62 in pre-market trading after Royalty Pharma announced that its buyout proposal for the company has expired. |
|
| June 17, 2013 |
| 07:28 EDT |  | VRTX | Cambridge Healthtech Institute to host a conference
Subscribe for More Information |
|
| June 14, 2013 |
| 09:38 EDT | | VRTX | Vertex has a conference call hosted by JPMorgan
Subscribe for More Information |
|
| 07:25 EDT | | VRTX | Vertex CF data positive, says RBC Capital
RBC Capital believes that data on Vertex's CF drug looked good and lowers the risk of the treatment. The firm expects the company to report good Phase III results for the drug in summer 2014, and it reiterates an Outperform rating on the stock. |
|
| June 12, 2013 |
| 07:33 EDT | | VRTX | European Cystic Fibrosis Society to host a conference
36th ECFS Conference is being held in Lisbon, Portugal on June 12-15. |
|
| June 11, 2013 |
| 14:37 EDT | | VRTX | SMC posts decision on Kalydeco resubmission to website
Subscribe for More Information |
|
| 07:31 EDT | | VRTX | Goldman to host a conference
Subscribe for More Information |
|
| June 5, 2013 |
| 10:25 EDT | | VRTX | Vertex says 6 abstracts from cystic fibrosis program to be presented at ECFS
Subscribe for More Information |
|
|
|
|
|
